BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16425127)

  • 1. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.
    Weinberg A; Tierney C; Kendall MA; Bosch RJ; Patterson-Bartlett J; Erice A; Hirsch MS; Polsky B;
    J Infect Dis; 2006 Feb; 193(4):488-93. PubMed ID: 16425127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
    HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.
    Bronke C; Palmer NM; Jansen CA; Westerlaken GH; Polstra AM; Reiss P; Bakker M; Miedema F; Tesselaar K; van Baarle D
    J Infect Dis; 2005 Mar; 191(6):873-80. PubMed ID: 15717261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
    Weinberg A; Wohl DA; Barrett RJ; van der Horst C
    J Infect Dis; 2001 Sep; 184(6):707-12. PubMed ID: 11517431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.
    Villacres MC; Lacey SF; La Rosa C; Krishnan R; Auge C; Longmate J; Zaia JA; Leedom JM; Diamond DJ
    J Infect Dis; 2001 Aug; 184(3):256-67. PubMed ID: 11443550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human cytomegalovirus (HCMV)-specific CD4+ T lymphocyte response in AIDS patients with no past or current HCMV disease following HAART.
    Tamarit A; Alberola J; Mir A; Benet I; Mira JV; Muñoz C; Galindo MJ; Navarro D
    J Clin Virol; 2004 Apr; 29(4):308-14. PubMed ID: 15018860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shift of CMV-specific CD4+ T-cells to the highly differentiated CD45RO-CD27- phenotype parallels loss of proliferative capacity and precedes progression to HIV-related CMV end-organ disease.
    Bronke C; Jansen CA; Westerlaken GH; De Cuyper IM; Miedema F; Tesselaar K; van Baarle D
    Clin Immunol; 2007 Aug; 124(2):190-9. PubMed ID: 17556025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.
    Komanduri KV; Feinberg J; Hutchins RK; Frame RD; Schmidt DK; Viswanathan MN; Lalezari JP; McCune JM
    J Infect Dis; 2001 Apr; 183(8):1285-9. PubMed ID: 11262214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
    Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
    Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy.
    Jacobson MA; Schrier R; McCune JM; Torriani FJ; Holland GN; O'Donnell JJ; Freeman WR; Bredt BM
    J Infect Dis; 2001 May; 183(9):1399-404. PubMed ID: 11294673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.
    French M; Keane N; McKinnon E; Phung S; Price P
    HIV Med; 2007 Apr; 8(3):148-55. PubMed ID: 17461858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
    Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
    Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections.
    Sindhu S; Toma E; Cordeiro P; Ahmad R; Morisset R; Menezes J
    J Med Virol; 2006 Apr; 78(4):431-9. PubMed ID: 16482539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery.
    Singh KP; Howard JL; Wild SP; Jones SL; Hoy J; Lewin SR
    Clin Immunol; 2007 Aug; 124(2):200-6. PubMed ID: 17574925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between cytomegalovirus-specific reactivity of T cell subsets and development of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
    Hsieh SM; Pan SC; Hung CC; Tsai HC; Chen MY; Chang SC
    J Infect Dis; 2001 Dec; 184(11):1386-91. PubMed ID: 11709780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype.
    Sinclair E; Tan QX; Sharp M; Girling V; Poon C; Natta MV; Jabs DA; Inokuma M; Maecker HT; Bredt B; Jacobson MA;
    J Infect Dis; 2006 Dec; 194(11):1537-46. PubMed ID: 17083038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of highly active antiretroviral therapy on cytomegalovirus viraemia in the absence of specific anti-cytomegalovirus therapy.
    Mihăilescu R; Arama V; Paraschiv S; Streinu-Cercel A; Oţelea D; Munteanu D; Iosipenco M; Chiotan C; Benea OE; Mărdărescu M; Rădulescu M; Hristea A; Ungurianu R; Aramă SS; Cercel AS; Călin R; Băicuş C
    Rom J Intern Med; 2008; 46(4):305-11. PubMed ID: 19480296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity.
    Springer KL; Weinberg A
    J Antimicrob Chemother; 2004 Sep; 54(3):582-6. PubMed ID: 15282241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients.
    Barron MA; Gao D; Springer KL; Patterson JA; Brunvand MW; McSweeney PA; Zeng C; Barón AE; Weinberg A
    Clin Infect Dis; 2009 Dec; 49(12):1777-83. PubMed ID: 19911937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity.
    Jansen CA; Piriou E; De Cuyper IM; van Dort K; Lange JM; Miedema F; van Baarle D
    Antivir Ther; 2006; 11(1):105-16. PubMed ID: 16518966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.